Novel biologically based therapeutic strategies in myeloma

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue 3, 2002, Pages 301-324

  Gupta, Deepak ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AE 941; ARSENIC TRIOXIDE; BETA LAPACHONE; BORTEZOMIB; DEXAMETHASONE; GLUTARIMIDE DERIVATIVE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; LONAFARNIB; MYELOMA ANTIGEN; OBLIMERSEN; PACLITAXEL; PHOSPHODIESTERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; S 3 AMINOPHTHALIMIDOGLUTARIMIDE; TELOMERASE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TIPIFARNIB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CELL; CYTOTOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; REMISSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TUMOR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; HUMANS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0036760132     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2002.00082.x     Document Type: Review

References (169)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin, 49: 8-31, 1999.
2. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93: 55-65, 1999.
3. Teoh G, Urashima M, Greenfield EA, et al. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest, 101: 1379-1388, 1998.
4. Tai Y-T, Teoh G, Lin B, et al. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol, 165: 6347-6355, 2000.
5. Tai Y-T, Podar K, Kraeft S-K, et al. Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: Functional implications. Exp Hematol, 30: 212-220, 2002.
6. Zhu C, Bogue MA, Lim DS, et al. Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell, 86: 379-389, 1996.
7. Casellas R, Nussenzweig A, Wuerffel R, et al. Ku80 is required for immunoglobulin isotype switching. EMBO J 17: 2404-2411, 1998.
8. Difilippantonio MJ, Zhu J, Chen HT, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature, 404: 510-514, 2000.
9. Anderson KC, Jones RC, Morimoto C, et al. Response of purified myeloma cells to hematopoietic growth factors. Blood, 73: 1915-1924, 1989.
10. Barut BA, Zon LI, Cochran MK, et al. Role of interleukin-6 in the growth of myeloma derived cell lines. Leukemia Res, 16: 951-959, 1992.
11. Paul PD, Barut BA, Cochran MK, et al. Lack of a role of interleukin-11 in the growth of multiple myeloma. Leukemia Res, 16: 247-252, 1992.
12. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor β1: Differential effects on multiple myeloma versus normal B cells. Blood, 87: 1928-1938, 1996.
13. Chauhan D, Kharbanda SM, Ogata A, et al. Oncostatin M induces association of GRB2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med, 182: 1801-1806, 1995.
14. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor α in the pathophysiology of multiple myeloma: Therapeutic applications. Oncogene, 20: 4519-4527, 2001.
15. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggered signaling cascades mediating multiple myeloma cell growth and migration. Blood, 98: 428-435, 2001.
16. Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood, 88: 2219-2227, 1996.
17. Ogata A, Chauhan D, Teoh G, et al. Interleukin-6 triggers cell growth via the ras dependent mitogen activated protein kinase (MAPK) cascade. J Immunol, 159: 2212-2221, 1997.
18. Ogata A, Chauhan D, Urashima M, et al. Blockade of MAPK signaling in interleukin-6 independent multiple myeloma cells. Clin Cancer Res, 3: 1017-1022, 1997.
19. Ogata A, Anderson KC. Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Leukemia Res, 20: 303-307, 1996.
20. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 15: 837-843, 1997.
21. Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK-2 dependent and independent apoptosis in multiple myeloma. Oncogene, 18: 6733-6740, 1999.
22. Chauhan D, Pandey P, Ogata A, et al. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma. J Biol Chem, 272: 29995-29997, 1997.
23. Chauhan D, Rosen S, Reed JR, et al. Apaf-1/cytochrome c independent and Smac dependent induction of apoptosis in multiple myeloma cells. J. Biol Cbem, 276: 24453-24456, 2001.
24. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and SAP kinase activation in multiple myeloma. Blood, 89: 227-234, 1997.
25. Urashima M, Teoh G, Chauhan D, et al. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon in multiple myeloma cells. Blood, 90: 279-289, 1997.
26. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of Interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. Biol Chem, 275: 27845-27850, 2000.
27. Chauhan D, Anderson KC. Apoptosis in multiple myeloma: Therapeutic implications. Apoptosis, 6: 47-56, 2001.
28. Chauhan D, Auclair D, Robinson EK, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene, 21: 1346-1358, 2002.
29. Hideshima T, Nakamura N, Chauhan D, et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20: 5991-6000, 2001.
30. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer, 79: 451-455, 1999.
31. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93: 3064-3073, 1999.
32. D'Amato RJ, Loughman MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 91: 4062-4085, 1994.
33. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341: 1566-1571, 1999.
34. Raje N, Anderson KC. Thalidomide-A revival story. N Engl J Med, 341: 1606-1609, 1999.
35. Parman T, Wiley MJ, Wells PG. Free radical mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med, 5: 582-585, 1999.
36. Geitz H, Handt S, Zwingengerger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 32: 213-221, 1996.
37. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood, 91: 3-21, 1998.
38. Bellamy W, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptor in hematological malignancies. Cancer Res, 59: 728-733, 1999.
39. Haslett PAJ, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subsets. J Exp Med, 187: 1885-1892, 1998.
40. Corral LG, Haslet PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNFα. J Immunol, 163: 380-386, 1999.
41. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96: 2943-2950, 2000.
42. Gupta D, Treon SP, Shima Y, et al. Adhesion of human multiple myeloma cell lines to bone marrow stromal cells stimulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia, 15: 1950-1961, 2001.
43. Davies FE, Lentzsch S, Young G, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98: 210-216, 2001.
44. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B cell malignancies. J Immunotherapy, 24: 263-271, 2001.
45. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, in press, 2002.
46. Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res, 62: 2300-2305, 2002.
47. King RW, Deshaies RJ, Peters JM, et al. How proteolysis drives the cell cycle. Science, 274: 1652-1659, 1996.
48. Herrmann JL, Briones F, Brisbay S, et al. Prostate carcinoma death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17: 2889-2899, 1998.
49. Li B, Dou Q. Bax degradation by the ubiquitin/proteasome-dependent pathway. Involvement in tumor survival and progression. Proc Natl Acad Sci USA, 97: 3850-3855, 2000.
50. Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin proteasome pathway is required for processing the NFκB precursor protein and the activation of NFκB. Cell, 78: 773-785, 1994.
51. Elliott PJ, Pien CS, McCormack ID, et al. Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol, 104: 1-7, 1999.
52. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res, 58: 4342-4348, 1998.
53. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res, 5: 2638-2645, 1999.
54. Harbison MT, Bruns CJ, Bold RJ, et al. Proteasome inhibitor PS-341 is effective as a anti-angiogenic agent in the treatment of human pancreatic carcinoma via inhibition of NFκB and subsequent inhibition of vascular endothelial growth factor production. Proc Am Assoc Cancer Res, 41: 71, 2000.
55. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61: 3071-3076, 2001.
56. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NFkB. Blood, 87: 1104-1112, 1996.
57. Richardson PG, Berenson J, Irwin D, et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following frontline therapy and are refractory to their most recent therapy. Blood, 98: 774a, 2002.
58. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem, in press, 2002.
59. Garrett R, Durie B, Nedwin G, et al. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med, 317: 526-532, 1987.
60. Lichtenstein A, Berenson J, Norman D, et al. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood, 74: 1266-1273, 1989.
61. Sati H, Greaves M, Apperley J, et al. Expression of interleukin-1β and tumor necrosis factor α in plasma cells from patients with multiple myeloma. Br J Haematol, 104: 350-357, 1999.
62. Davies FE, Rollinson S, Rawstron A, et al. High producer haplotypes of tumor necrosis factor α and lymphotoxin are associated with an increased risk of myeloma and have an improved progression free survival after treatment. J Clin Oncol, 18: 2843-2851, 2000.
63. Ray A, Sassone-Corsi S, Sehgal P. A multiple cytokine and second messenger responsive element in the enhancer of the human interleukin-6 gene: Similarities with c-fos gene regulation. Mol Cell Biol, 9: 5537-5547, 1989.
64. Li P, Sanz I, O'Keefe RJ, et al. NFκB regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol, 164: 5990-5997, 2000.
65. Dankbar B, Padro T, Leo T, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor stromal cell interactions in multiple myeloma. Blood, 95: 2630-2636, 2000.
66. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kinase-dependent PKCα activation. J Biol Chem, 277: 7875-7881, 2002.
67. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res, 62: 5019-5026, 2002.
68. Chauhan D, Catley L, Hideshima T, et al. 2-Methoxyestradiol inhibits growth of multiple myeloma cells in the bone marrow microenvironment. Blood, in press 2002.
69. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist, 6 (Suppl. 2): 3-10, 2001.
70. Rousselot P, Labaume S, Marolleau J-P, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res, 59: 1041-1048, 1999.
71. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res, 60: 3065-3071, 2000.
72. Gallagher RE. Co-biomodulation with arsenic trioxide in multiple myeloma. Leuk Res, 25: 237-239, 2001.
73. Chen G-Q, Zhu XH, Shen Y-L, et al. Pharmacologic concentrations of arsenic trioxide induces growth inhibition and apoptosis in malignant lymphocytes and multiple myeloma cells. Blood, 92 (Suppl. 1, Part 1): 638a, 1998.
74. 2 family members. Blood, 92 (Suppl. 1, Part 1): 638a, 1998.
75. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer, 1: 851-860.
76. Munshi NC. Arsenic trioxide: An emerging therapy for multiple myeloma. Oncologist, 6 (Suppl. 2): 17-21, 2001.
77. 3) on myeloma cells. Leuk Res, 25: 227-235, 2001.
78. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 96: 1525-1530, 2000.
79. Lew YS, Brown SL, Griffin RJ, et al. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res, 59: 6033-6037, 1999.
80. 3-resistant APL cells. Proc Am Assoc Cancer Res, 42: 786a, 2001.
81. Grad JM, Bahlis NJ, Reis I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 98: 805-813, 2001.
82. Gartenhaus RB, Prachand S, Gordon LI. Enhanced cytotoxicity to arsenic trioxide in resistant multiple myeloma by butathione sulfoxime (BSO). Blood, 96 (Suppl. 11): 758a-759a, 2000.
83. Dai J, Weinberg RS, Waxman S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93: 268-277, 1999.
84. Boise LH, Lee KP, Reis I, et al. Role of glutathione depletion in arsenic-based treatment. VIIIth International Myeloma Workshop of the Multiple Myeloma Research Foundation, Banff, Alberta, Canada, May 4-8, 2001.
85. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood, 98: 795-804, 2001.
86. Mitsiades N, Mitsiades CS, Poulaki V, et al. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood, 99: 2162-2178, 2002.
87. Mitsiades N, Mitsiades CS, Poulaki V, et al. Concepts in the use of TRAIL/Apo2L: An emerging biotherapy for myeloma and other neoplasias. Expert Opin Invest Drugs, 10: 1521-1530, 2001.
88. Falardeau P, Champague P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol, 28: 620-625, 2001.
89. Dupont E, Falardeau P, Mousa SA, et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis, 19: 145-153, 2002.
90. Gingras D, Renaud A, Mousseau N, et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res, 21: 145-155, 2001.
91. Beliveau R, Gingras D, Kruger EA, et al. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factormediated biological effects. Clin Cancer Res, 8: 1242-1250, 2002.
92. Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol, 20: 299-303, 2002.
93. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a Phase II trial with two dose levels. Ann Oncol, in press, 2002.
94. Harada N, Hata H, Yoshida M, et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia, 12: 1817-1820, 1998.
95. Pettersson M, Jernberg-Wiklund H, Larsson LG, et al. Expression of bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood, 79: 495-502, 1992.
96. Miguel-Garcia A, Orero T, Matutes E, et al. bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: A comparative study. Haematologica, 83: 298-304, 1998.
97. Brown RD, Pope B, Luo XF, et al. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymphoma, 16: 147-156, 1994.
98. Hamilton MS, Barker HF, Ball J, et al. Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia, 5: 768-771, 1991.
99. Ong F, van Nieuwkoop JA, de Groot-Swings GM, et al. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia, 12: 220-229, 1998.
100. Sangfelt O, Osterborg A, Grander D, et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer, 63: 190-192, 1995.
101. Gazitt Y, Fey V, Thomas C, et al. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol, 13: 397-405, 1998.
102. Crooke ST. Therapeutic application of oligonucleotides. Ann Rev Pharmacol Toxicol, 32: 329-376, 1992.
103. van de Donk N, Kamphuis M, van Dijk M, et al. Evaluation of bcl-2 antisense oligonucleotide drugs in multiple myeloma. VIIIth International Myeloma Workshop Abstract Book. University of Alberta, Canada, p. 201, 2001.
104. Gazitt Y, Liu Q. Bcl-2 Antisense (Genasense™) Down-Regulates bcl-2 Protein and Potentiates Cytotoxic Chemotherapy in Drug-Resistant Myeloma. 6th Annual European Hematology Association, City, 2001.
105. Drach J, Kaufmann H, Urbauer E, et al. The biology of multiple myeloma. J Cancer Res Clin Oncol. 126: 441-447, 2000.
106. Neri A, Knowles DM, Greco A, et al. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA, 86: 9268-9272, 1988.
107. Liu P, Quam L, Billadeau D, et al. Activating mutations of N- and K-ras in multiple myeloma show distinct clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III trial. Blood, 88: 2699-2706, 1996.
108. Kato K, Cox AD, Hisaka MM, et al. Isoprenoid addition to Ras is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA, 89: 6403-6407, 1992.
109. Sebti SM, Hamilton AD. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Therapeutics, 74: 103-114, 1997.
110. Adjei AA, Davis JN, Bruzek LM, et al. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res, 7: 1438-1445, 2001.
111. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood, 97: 3361-3369, 2001.
112. Schaffner-Sabba K, Schmidt-Ruppin KH, Wehrli W, et al. β-lapachone: Synthesis of derivatives and activities in tumor models. J Med Chem, 27: 990-994, 1984.
113. Li CJ, Li Y-Z, Pinto AV, et al. Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA, 96: 13369-13374, 1999.
114. Gupta D, Podar K, Lin B, et al. β-lapachone, a novel plant product overcomes drug resistance in human multiple myeloma cells. Exp Hem, in press, 2002.
115. Li Y-Z, Li CJ, Pinto AV, et al. Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by β-lapachone in human carcinoma cells. Mol Med, 5: 232-239, 1999.
116. Pratt WB. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Ann Rev Pharmacol Toxicol, 37: 297-326, 1997.
117. Stancato LF, Silverstein AM, Owens-Grillo JK, et al. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Rafkinase. J Biol Chem, 272: 4013-4020, 1997.
118. Lewis J, Devin A, Miller A, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem, 275: 10519-10526, 2000.
119. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J, 19: 4310-4322, 2000.
120. Mitsiades CS, Mitsiades N, Poulaki V, et al. The HSP90 molecular chaperone as a novel therapeutic target in hematological malignancies. Blood, 98: 377a, 2001.
121. Workman P, Maloney A. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther, 2: 3-24, 2002.
122. Byrd JC, Shinn C, Ravi R, et al. Desipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood, 94: 1401-1408, 1999.
123. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA, 97: 10014-10019, 2000.
124. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res, 61: 2-7, 2001.
125. Mitsiades N, Mitsiades CS, Poulaki V, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in multiple myeloma (MM) and Waldenstrom's Macroglobulinemia (WM) cell lines and patient tumor cells. Blood, 98: 376a, 2001.
126. Kelland LR. Telomerase: Biology and phase I trials. Lancet Oncol, 2: 95-102, 2001.
127. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91: 25-34, 1997.
128. Zhang X, Mar V, Zhou W, et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev, 13: 2388-2399, 1999.
129. Herbert B-S, Pitts AE, Baker SE, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA, 96: 14726-14781, 1999.
130. Corey DR. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene, 21: 631-637, 2002.
131. Shea-Herbert B, Pongracz K, Shay JW, et al. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene, 21: 638-642, 2002.
132. Gowan SM, Harrison JR, Patterson L, et al. A G-Quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol, 61: 1154-1162, 2002.
133. Anderson KC. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. In: European Haematology Association Educational Book, Green AR (ed). Macmillan, Hampshire, England, pp. 42-45, 2000.
134. Anderson KC. Multiple myeloma: New insights and therapeutic approaches. In: American Society of Hematology Education Book, Schechter GP, Berliner N, Telen MJ (eds). Publisher, Publisher City, pp. 159-165, 2000.
135. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 91: 3671-3680, 1998.
136. Lokhorst HM, Schattenberg JJ, Cornelissen JJ, et al. Donor lymphocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90: 4206-4211, 1997.
137. Alyea EP, Weller E, Schlossman RL, et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood, 98: 934-939, 2001.
138. Alyea EP, Weller E, Schlossman RL, et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Reduced transplant related toxicity with preservation of graft-versus-myeloma effect. VIIIth International Myeloma Workshop Abstract Book, University of Alberta, Canada, p. 154, 2001.
139. Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant, 6: 375-386, 2000.
140. Orsini E, Alyea EP, Schlossman R, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graftversus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant, 25: 623-632, 2000.
141. Alyea EP, Neuberg Donna Canning C, et al. Nonmyeloablative conditioning with low dose intravenous busulfan and fludarabine is safe and sufficient to obtain allogeneic stem cell engraftment in patients with hematological malignancies. Blood, 98: 185a, 2001.
142. Bellucci R, Wu CJ, Munshi NC, et al. Identification of target antigens associated with graft-vs-myeloma response after allogeneic bone marrow transplantation and donor lymphocyte infusion. Blood, 98: 405a, 2001.
143. Anderson KC, Andersen J, Soiffer R, et al. Monoclonal antibody purged bone marrow transplantation therapy for multiple myeloma. Blood, 82: 2568-2576, 1993.
144. Seiden MV, Schlossman R, Andersen J, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma, 17: 87-93, 1995.
145. + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood, 93: 1-13, 1999.
146. Stewart AK, Vesico R, Schiller G, et al. Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall or progression free survival following high dose chemotherapy for multiple myeloma: Results of a multi-center randomized controlled trial. J Clin Oncol, 19: 3771-3779, 2001.
147. Teoh G, Chen L, Urashima M, et al. Adenovirus vector based purging of multiple myeloma cells. Blood, 92: 4591-4601, 1998.
148. Schultze JL, Anderson KC, Gilleece MH, et al. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin-2. Br J Haematol, 113: 455-460, 2001.
149. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest, 100: 2757-2765, 1997.
150. Von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application. Blood, 99: 3319-3325, 2002.
151. Teoh G, Tai YT, Greenfield EA, et al. Tumor rejection antigen 1 (GRP94) expression is induced by CD40 ligand activation of multiple myeloma cells and mediates allogeneic T cell reactivity. Blood, 92 (Suppl. 1): 101a, 1998.
152. Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood, 93: 1287-1298, 1999.
153. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res, 61: 6846-6850, 2001.
154. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA, 97: 2715-2718, 2000.
155. Gong J, Nikrui N, Chen D, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol, 165: 1705-1711, 2000.
156. Tanaka Y, Koido S, Chen D, et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol, 101: 192-200, 2001.
157. Raje N, Gong J, Chauhan D, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpes virus gene sequences. Blood, 93: 1487-1495, 1999.
158. Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99: 2512-2517, 2002.
159. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T cell epitopes expressed commonly in B cell malignancies. Nat Med, 6: 667-672, 2000.
160. Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10: 673-679, 1999.
161. Maecker B, Sherr DH, Shen C, et al. Targeting universal tumor antigens with cytotoxic T cells: Potential of CYP1B1 for broadly applicable antigen-specific immunotherapy. Blood, 94 (Suppl. 1): 43a, 1999.
162. Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma. Blood, 84: 3017-3025, 1994.
163. Grossbard ML, Fidias P, Kinsella J, et al. Anti-B4 blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol, 102: 509-515, 1998.
164. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cells malignancies. Semin Oncol, 27: 598-613, 2000.
165. Treon SP, Shima Y, Grossbard ML, et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol, 11 (Suppl. 1): 107-111, 2000.
166. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol, 27: 79-85, 2000.
167. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications. J Immunother, 25: 72-81, 2002.
168. Treon SP, Maimonis P, Bua D, et al. Elevated soluble MUC-1 levels and decreased anti-MUC-1 antibody levels in patients with multiple myeloma. Blood, 96: 3147-3153, 2000.
169. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's Macroglobulinemia. J Immunother, 24: 272-279, 2001.